| |
Significant patient populations, top clinical institutions, and ease of
regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠
|
|
Today's Big NewsOct 25, 2022 |
| By Max Bayer Biogen may still be basking in the positive phase 3 data of its Eisai-partnered Alzheimer’s drug lecanemab, but the big pharma's CEO has remained vague on exactly what role his company will play in the therapy's commercialization. |
|
|
|
By Nick Paul Taylor The CD40 space has claimed another victim. One year after disclosing a kidney transplant flop, Novartis has stopped work on iscalimab in liver transplantation after a phase 2 trial delivered lackluster results. |
By Nick Paul Taylor GSK has axed its NY-ESO-1 T-cell receptor pact with Lyell Immunopharma, with the Big Pharma transferring the program to Adaptimmune. It means that months after stopping enrollment in a study of its first-generation NY-ESO-1 candidate, GSK has walked away from a $1 billion-plus pact with Lyell that could have delivered enhanced successors. |
By James Waldron Astellas will sink $50 million into Taysha Gene Therapies in exchange for a 15% stake in the biotech and the option to license its clinical-stage candidates for two rare neurological disorders. |
By Gabrielle Masson Diffusion Pharmaceuticals is evaluating its options amid the prolonged bear market, including partnerships, licensing deals, divestiture for some of its tech or selling off the whole biotech. |
By Gabrielle Masson Though many COVID-19 treatments are in development, few have yet to cross the approval threshold in the U.S. or Europe. French biotech Inotrem hopes to change that, posting phase 2 data that show its only clinical-stage compound could help critically ill COVID patients. |
By Angus Liu Broadly neutralizing antibodies hold promise as potential longer-term HIV options, and GSK’s ViiV Healthcare has provided encouraging early proof-of-concept data for such a candidate it licensed from the NIH. |
By Helen Floersh Neurons in the part of the brain that controls the fear response may also be responsible for the tendency to overeat fatty, sugary foods. |
By Angus Liu Novartis’ gene therapy Zolgensma ranks among six drugs that the Swiss pharma counts as its major growth drivers with multibillion-dollar peak sales potential. But the drug was missing from a list of the company's top performers in the third quarter. |
By Heather Landi 23andMe is focused on using Lemonaid Health's virtual care and online pharmacy capabilities to build out genetically-driven telehealth and pharmacogenomic services. |
By Fraiser Kansteiner Should its Eisai-partnered Alzheimer's disease prospect lecanemab win an approval at the FDA this coming January, Biogen already has facilities on deck to crank out the amyloid plaque-busting antibody, plus “a little over $100 million of inventory on hand as of the end of the quarter,” the company's CFO said Tuesday. |
By Andrea Park Verily is on the up-and-up—as in, re-upping a team-up with the Crohn’s and Colitis Foundation to help spur research into inflammatory bowel disease forward. |
By Dave Muoio The suspect was on parole for aggravated robbery and was permitted to visit the hospital with an ankle bracelet as his girlfriend gave birth, according to the Dallas Police Department. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Wednesday, November 2, 2022 | 1pm ET / 10am PT This webinar will discuss how Invitae and others are working together to characterize the lived experience of patients with rare bile duct cancer, and ultimately, improve patient care. Register now.
|
|
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
